Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Imagine Drucker submitting a grant proposal today titled "Investigating Gila Monster Venom Proteins for Potential Therapeutic Applications." How would reviewers respond to: Unclear commercial potential No obvious connection to existing treatment paradigms High risk of "failure" (most venom studies don't yield drugs) Difficult to measure short-term impact Traditional funding metrics, publication counts, citation indices, immediate clinical relevance, would likely work against such proposals
With this degree of weight loss in only 48 weeks, we see people having improvement or resolution in other conditions like hypertension, hyperlipidemia, osteoarthritis, sleep apnea, and more weight-related conditions, Billings said
Lixisenatide and beinaglutide Lixisenatide and beinaglutide, including EX-BID as discussed earlier, are classified as short-acting GLP-1RAs based on pharmacokinetic characteristics such as clearance half-life and concentration-time distribution
Mechanism of hard-nanomaterial clearance by the liver
Bioprocess Engineering Principles 2nd edn 653655 (Academic, 2012)
US$ 26.59
US$ 28.43
US$ 29.14
US$ 24.39
